Experts say a new drug could mean the "beginning of the end" in the search for effective Alzheimer's treatments.
Clinicial trials of Lecanamab found that after 18 months it slowed disease progression by over a quarter compared with patients taking the placebo.
Peter Kelham - from Alzheimers Research Uk - says the results are the most significant step forward he he has seen.
IN: 'This is...
OUT: ...patients.'
DUR: 27 seconds
Clinicial trials of Lecanamab found that after 18 months it slowed disease progression by over a quarter compared with patients taking the placebo.
Peter Kelham - from Alzheimers Research Uk - says the results are the most significant step forward he he has seen.
IN: 'This is...
OUT: ...patients.'
DUR: 27 seconds